within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX36_Oblimersen;

model Oblimersen
  extends Pharmacolibrary.Drugs.ATC.L.L01XX36;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XX36</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oblimersen is an antisense oligonucleotide designed to target the messenger RNA of the BCL-2 protein, inducing apoptosis in tumor cells by reducing BCL-2 expression. Investigated in several cancers, especially chronic lymphocytic leukemia and melanoma, oblimersen has not gained regulatory approval and is not currently in widespread clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from literature, typical oncology intravenous dosing in adults; population: adult cancer patients.</p><h4>References</h4><ol><li><p>Galatin, PS, et al., &amp; Sikic, BI (2011). Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. <i>Investigational new drugs</i> 29(5) 971–977. DOI:<a href=&quot;https://doi.org/10.1007/s10637-010-9416-4&quot;>10.1007/s10637-010-9416-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20349264/&quot;>https://pubmed.ncbi.nlm.nih.gov/20349264</a></p></li><li><p>Margolin, K, et al., &amp; Gandara, DR (2007). Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of cancer research and clinical oncology</i> 133(10) 705–711. DOI:<a href=&quot;https://doi.org/10.1007/s00432-007-0200-6&quot;>10.1007/s00432-007-0200-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17508219/&quot;>https://pubmed.ncbi.nlm.nih.gov/17508219</a></p></li><li><p>O&#x27;Brien, SM, et al., &amp; Rai, KR (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 23(30) 7697–7702. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2005.02.4364&quot;>10.1200/JCO.2005.02.4364</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16186597/&quot;>https://pubmed.ncbi.nlm.nih.gov/16186597</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Oblimersen;
